The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 01, 2022
Filed:
Nov. 03, 2016
The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);
The Trustees of Columbia University IN the City of New York, New York, NY (US);
Peter Kwong, Washington, DC (US);
Young Do Kwon, Kensington, MD (US);
Ivelin Georgiev, Nashville, TN (US);
Gilad Ofek, Gaithersburg, MD (US);
Baoshan Zhang, Bethesda, MD (US);
Krisha McKee, Columbia, MD (US);
John Mascola, Rockville, MD (US);
Mark Connors, Bethesda, MD (US);
Gwo-Yu Chuang, Rockville, MD (US);
Sijy O'Dell, Silver Spring, MD (US);
Robert Bailer, Adamstown, MD (US);
Mark Louder, Mt. Airy, MD (US);
Mangaiarkarasi Asokan, Rockville, MD (US);
Richard Schwartz, Bethesda, MD (US);
Jonathan Cooper, Arlington, VA (US);
Kevin Carlton, Gaithersburg, MD (US);
Michael Bender, Washington, DC (US);
Amarendra Pegu, Potomac, MD (US);
Lawrence Shapiro, New York, NY (US);
Tatyana Gindin, New York, NY (US);
Lisa Kueltzo, Gaithersburg, MD (US);
The United States of America, as represented by the Sectetary, Department of Health and Human Services, Bethesda, MD (US);
The Trustees of Columbia University in the City of New York, New York, NY (US);
Abstract
Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.